The above results showed that CAR T cells from GPR65 KO and m.CR tumors retained effector functionality despite their inability to clear the GPR65 KO tumors and indicated that GPR65 KO tumor cells did not confer CAR T resistance through downregulation of CD19 expression or impairment of CAR T-cell expansion and function. This evidence concerns the gene GPR65 and neoplasm.